Immunization with a DNA vaccine cocktail induces a Th1 response and protects mice against Mycobacterium avium subsp.

Sung-Un Park1, Kumanan Kathaperumal, Sean McDonough

  • 1College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.

Vaccine
|June 28, 2008
PubMed

Insights

This study developed a recombinant DNA vaccine using Mycobacterium antigens. Immunization reduced bacterial load and improved immune responses in mice, indicating potential protection against mycobacterial infections.

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Mycobacterium avium subsp. paratuberculosis (MAP) infection poses a significant challenge.
  • Previous research identified key MAP antigens (85A, 85B, 85C, SOD, 35kDa) that elicit Th1-associated immune responses.

Purpose of the Study:

  • To develop and evaluate a recombinant DNA vaccine expressing selected MAP antigens.
  • To assess the vaccine's efficacy in inducing protective immunity against MAP infection in a mouse model.

Main Methods:

  • Cloning and expression of MAP antigen genes (85A, 85B, 85C, SOD, 35kDa) into a eukaryotic plasmid (pVR1020).
  • Immunization of C57BL/6 mice with the recombinant DNA cocktail or control plasmid.
  • Evaluation of bacterial burden, histopathology, T cell responses (CD4+, CD8+), lymphocyte proliferation, and Th1 cytokine (IFN-gamma) levels.

Main Results:

  • DNA vaccine significantly reduced MAP bacterial burden in the spleen and liver.
  • Histopathology showed reduced granulomas and acid-fast bacilli in vaccinated mice.
  • Vaccination induced robust CD4+ and CD8+ T cell responses, lymphocyte proliferation, and increased IFN-gamma levels.

Conclusions:

  • Recombinant DNA vaccine expressing MAP antigens elicits protective immunity.
  • The vaccine induces a Th1-biased immune response, crucial for controlling mycobacterial infections.
  • This approach shows promise for developing effective vaccines against MAP.